A. Nishida

发表

Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.

T. Okumura, K. Haruma, S. Fukudo, 2016, Gastroenterology.

Characterization of YM022: its CCKB/gastrin receptor binding profile and antagonism to CCK-8-induced Ca2+ mobilization.

A. Nishida, K. Honda, H. Yazawa, 1994, European journal of pharmacology.

Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula.

A. Nishida, S. Akuzawa, K. Miyata, 1998, Arzneimittel-Forschung.

(3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)- 1H-1,4-benzodiazepin-3-yl)-N′-(3(methylamino)phenyl)urea (YF476): A Potent and Orally Active Gastrin/CCK-B Antagonist.

A. Nishida, H. Ryder, S. Akuzawa, 1997 .

YF476 is a new potent and selective gastrin/cholecystokinin‐B receptor antagonist in vitro and in vivo

A. Nishida, S. Akuzawa, K. Miyata, 1997, Alimentary pharmacology & therapeutics.

(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.

A. Nishida, H. Ryder, S. Akuzawa, 1997, Journal of medicinal chemistry.

Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression.

A. Nishida, S. Akuzawa, Y. Nagakura, 1995, The American journal of physiology.

L-365,260, a potent CCK-B/gastrin receptor antagonist, suppresses gastric acid secretion induced by histamine and bethanechol as well as pentagastrin in rats.

A. Nishida, K. Honda, K. Miyata, 1992, Japanese journal of pharmacology.

Cultural adaptation: translatability assessment and linguistic validation of the patient-reported outcome instrument for irritable bowel syndrome with diarrhea

K. Lasch, A. Nishida, R. Arbuckle, 2016, Patient related outcome measures.

Translatability Assessment and Linguistic Validation of The Patient-Reported Outcome Instrument for Irritable Bowel Syndrome With Diarrhea (Ibs-D Pro).

K. Lasch, A. Nishida, R. Arbuckle, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Gastric mucosal protection by YM638, a novel leukotriene D4 receptor antagonist, in rats.

A. Nishida, K. Miyata, T. Kamato, 1995, European journal of pharmacology.

Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets.

A. Nishida, K. Miyata, Y. Nagakura, 1993, European journal of pharmacology.

Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex

A. Nishida, S. Akuzawa, K. Miyata, 1995, Neuropharmacology.

Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation.

A. Nishida, K. Hidaka, K. Miyata, 1993, European journal of pharmacology.

YM022, A Potent and Selective Gastrin/CCK-B Receptor Antagonist, Inhibits Peptone Meal-Induced Gastric Acid Secretion in Heidenhain Pouch Dogs

A. Nishida, S. Akuzawa, K. Miyata, 1997, Digestive Diseases and Sciences.

Antagonistic effect of YM022, an antiulcer agent in rats, on human cholecystokinin (CCK)B/gastrin receptor.

A. Nishida, K. Honda, H. Yazawa, 1996, Japanese journal of pharmacology.

Antisecretory effects of a novel and long-lasting histamine H2-receptor antagonist, YM-14471, in rats and dogs.

A. Nishida, K. Miyata, H. Yuki, 1993, Japanese journal of pharmacology.

Identification and biological activity of novel peptidomimetic gastrin/CCK-B receptor agonists

A. Nishida, H. Ryder, K. Miyata, 1996 .

Effect of a selective 5-HT3 receptor agonist on gastric motility in fasted and fed dogs.

A. Nishida, K. Miyata, Y. Nagakura, 1997, European journal of pharmacology.

The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

A. Nishida, W. Krauwinkel, T. Kadokura, 2008, European Journal of Clinical Pharmacology.

Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.

A. Nishida, S. Akuzawa, K. Miyata, 1994, The Journal of pharmacology and experimental therapeutics.

Characterization of YM060, a potent and selective 5-hydroxytryptamine3 receptor antagonist, in rabbit nodose ganglion and N1E-115 neuroblastoma cells.

A. Nishida, K. Hidaka, K. Honda, 1992, The Journal of pharmacology and experimental therapeutics.

Role of the serotonin3 receptor in stress-induced defecation.

A. Nishida, K. Honda, K. Miyata, 1992, The Journal of pharmacology and experimental therapeutics.

Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea

S. Fukudo, M. Ida, H. Akiho, 2017, BioPsychoSocial Medicine.

Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea

S. Fukudo, M. Ida, H. Akiho, 2017, BioPsychoSocial Medicine.

Serotonin (5-HT)3 receptor blocking activities of YM060, a novel 4,5,6,7-tetrahydrobenzimidazole derivative, and its enantiomer in anesthetized rats.

A. Nishida, K. Miyata, R. Tsutsumi, 1991, The Journal of pharmacology and experimental therapeutics.

Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H- benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated tissue.

A. Nishida, K. Miyata, R. Tsutsumi, 1991, The Journal of pharmacology and experimental therapeutics.

Serotonin (5-HT)3-receptor antagonism of 4,5,6,7-tetrahydrobenzimidazole derivatives against 5-HT-induced bradycardia in anesthetized rats.

A. Nishida, K. Honda, K. Miyata, 1994, Japanese journal of pharmacology.

YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.

A. Nishida, S. Akuzawa, K. Miyata, 1994, The Journal of pharmacology and experimental therapeutics.

SYNTHESIS AND BIOLOGICAL ACTIVITY OF 1-ALKYLCARBONYLMETHYL ANALOGUES OF YM022

A. Nishida, H. Ryder, S. Akuzawa, 1996 .

Synthesis and biological activity of 5-heteroaryl benzodiazepines: analogues of YM022

A. Nishida, H. Ryder, S. Akuzawa, 1996 .

Comparative evaluation of the role of endogenous gastrin in basal acid secretion in conscious rats provided with chronic fistula and pylorus ligation.

A. Nishida, S. Akuzawa, K. Miyata, 1996, Japanese journal of pharmacology.

Pharmacological profile of YM022, a potent and selective gastrin/cholecystokinin-B receptor antagonist

A. Nishida, 1993 .

Characterization of 5-hydroxytryptamine (5-HT) receptor subtypes influencing colonic motility in conscious dogs

A. Nishida, K. Miyata, Y. Nagakura, 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

Histamine H2-receptor plays only a minor role in histamine-induced wheal response in the squirrel monkey and guinea pig.

A. Nishida, K. Honda, K. Miyata, 1993, Japanese journal of pharmacology.

Effects of 15(R)-15-methyl prostaglandin E2 (arbaprostil) on gastric secretion and various gastric lesions induced in rats.

A. Nishida, S Okabe, H Jino, 1986, Japanese journal of pharmacology.

Studies on the mechanism for the gastric mucosal protection by famotidine in rats.

A. Nishida, K. Honda, K. Miyata, 1991, Japanese journal of pharmacology.

Protective effect of cetraxate, a new antiulcer drug, against serotonin-induced ulcer.

A. Nishida, K. Hirokawa, T. Hashizume, 1979, Archives internationales de pharmacodynamie et de therapie.

Antisecretory and antiulcer effects of YM020, a new H+,K(+)-ATPase inhibitor, in rats and dogs.

A. Nishida, K. Miyata, M. Ohta, 1995, Japanese journal of pharmacology.

Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome

P. Marquis, A. Lembo, A. Nishida, 2014, Clinical and Translational Gastroenterology.

New 1,4-benzodiazepin-2-one derivatives as gastrin/cholecystokinin-B antagonists.

A. Nishida, T. Mase, K. Murase, 1995, Chemical & pharmaceutical bulletin.

New 1,4‐Benzodiazepin‐2‐one Derivatives as Gastrin/Cholecystokinin‐B Antagonists.

A. Nishida, T. Mase, K. Murase, 1996 .

The Irritable Bowel Syndrome-Diarrhea (IBS-D) Daily Symptom Diary and Event Log: A Newly Developed Patient-Reported Outcome (PRO) Measure

P. Marquis, K. Lasch, A. Nishida, 2011 .

The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

A. Nishida, W. Krauwinkel, T. Kadokura, 2008, European Journal of Clinical Pharmacology.